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Abstract
Nasopharyngeal carcinoma (NPC) is a tumor derived from epithelial cells and Epstein-Barr virus
infection has been reported to be a cause of this disease. Chemokine receptor CXCR4 was found
to be involved in HIV infection and was highly expressed in human malignant breast tumors and the
ligand for CXCR4, CXCL12 (SDF-1), exhibited high expression in organs in which breast cancer
metastases are often found. The metastatic pattern of NPC is quite similar to that of malignant
breast tumors. In this study, we investigated the expression of CXCR4 in nasopharyngeal
carcinoma (NPC) tissues by immunohistostaining. We found different staining patterns, which
included localization in the nucleus, membrane, cytoplasm or a combination of them. The staining
intensity was also variable among samples. The metastatic rates in patients with high compared to
low or absent expression was 38.6% versus 19.8%, respectively (P = 0.004). High expression of
CXCR4 was associated with poor overall survival (OS = 67.05% versus 82.08%, P = 0.0225). These
results suggest that CXCR4 may be involved in the progression of NPC and that a high level of
CXCR4 expression could be used as a prognostic factor.
Introduction
Nasopharyngeal carcinoma (NPC) is a tumor derived
from epithelial cells located in the posterior part of the
nasopharynx. The nasopharynx has an abundant supply
of regional lymphatic vessels, which drain along the inter-
nal jugular vein and the posterior cervical and retropha-
ryngeal chains. As a result, NPC frequently spreads
regionally leading to early lymph-node involvement in
the neck. Systemic dissemination also occurs more readily
than in other head-and-neck cancers, frequently involving
bones, lung, and liver [1]. Although the primary tumor is
sensitive to radiotherapy, NPC-related deaths occur
because of secondary spread of tumor cells. It has been
observed that at the time of diagnosis, 60–85% of NPC
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patients already have clinically detectable metastases in
the regional lymph nodes or distant organs such as the
lungs and bone [2]. Since there is no effective treatment
for NPC at the stage of metastasis, the prognosis remains
poor with a 5-year survival around 50%[3].
The metastatic process results from several sequential
steps and represents a highly organized, non-random,
organ-selective process [4]. Muller et al [5] found that the
chemokine receptor CXCR4 and CCR7 were highly
expressed in human malignant breast tumors compared
to normal breast tissue. The ligands for these receptors –
CXCL12 (SDF-1) for CXCR4 and CCL21 for CCR7 –
exhibit high expression in organs in which breast cancer
metastases are often found. The organ tropism of meta-
static NPC often recapitulates that observed in malignant
breast tumors. In addition, Staller et al [6] observed an
inverse correlation between CXCR4 expression and sur-
vival in patients with renal cell carcinoma (RCC). They
also noted that the von Hippel-Lindau tumor suppressor
protein pVHL negatively regulates CXCR4 expression
owing to its capacity to target hypoxia-inducible factor
(HIF) for degradation under normoxic conditions. The
process is suppressed under hypoxic conditions, resulting
in HIF-dependent CXCR4 activation. Interestingly, the
vHL gene is located at 3p26-3p25. This region displays
loss of heterozygosity in NPC and the loss of 3p26-13 has
been associated to early events in the carcinogenesis of
NPC [7,8].
The chemokine receptor CXCR4 is the only physiological
receptor for SDF-1 (a member of the CXC subfamily of
chemokines) [9-11]. Chemokines represent a large family
of about 50 proteins that modulate cell trafficking and
angiogenesis, during infection and inflammation and
play a significant role in the tumor microenvironment.
[12].
CXCR4 plays a major role in embryogenesis, homeostasis
and inflammation and can function as a coreceptor for T
lymphocytotrophic HIV-1 isolates [13,14]. CXCR4 is also
the only chemokine receptor which mRNA expression is
regulated during trophoblast differentiation in vitro [15].
Kobayashi et al reported that CXCR4 was down-regulated
during differentiation of viral antigen-specific CD8 (+) T
cells and could be used to distinguish subsets of CD8 (+)
T [16].
CXCR4 expression has been reported in several epithelial,
mesenchymal and haematopoietic cancers [17]. Recently
CXCR4 has been shown to be expressed by tumor cells in
breast cancer, non-small cell lung cancer, pancreatic can-
cer, prostate cancer, thyroid cancer and to play an impor-
tant role in their metastatic process [5,18-22]. Finally, Xu
Y et al found that CXCR4 was highly expressed in NPC cell
lines, and its expression was associated with differentia-
tion grade and proliferation ability of NPC cells [23].
Therefore, we asked whether CXCR4 expression is associ-
ated with the prognosis and differentiation of NPC. Con-
sidering its potential effect on the development of
metastases, we investigated the expression of CXCR4 in
NPC tissue by immunohistochemistry and observed that
high CXCR4 expression is associated with poor survival
independently of the differentiation status in NPC.
Materials and methods
Reagents and antibodies
The anti-CXCR4 mouse monoclonal antibody (MAB 172;
R&D Systems; dilution 1:600) was used for immunohisto-
chemical analysis. The PV-9000 Polymer Detection Sys-
tem was used for immunohistochemical staining
according to the manufacturer's recommendations
(Golden Bridge International, USA).
Nasopharyngeal carcinoma tissues
Immunohistochemistry was performed on undifferenti-
ated NPC carcinomas tissues collected from 194 patients
who were admitted to the Sun Yat-sen University Cancer
Center in the year 2000 and could be followed for three
years until 2004. We also analyzed 26 NPC tissue samples
of different histological subtype containing 10 undifferen-
tiated carcinomas, 10 differentiated carcinomas and 6
keratinising squamous cell carcinomas from these
patients admitted to the center from 2000 to 2004. All
samples were obtained with full patient consent.
Immunohistochemical analysis
Samples were fixed in 4% paraformaldehyde or 10% for-
malin and embedded in paraffin. Four mm sections were
cut and placed on silane-coated slides for immunohisto-
chemical studies. Part of the specimens was stained with
H&E and microscopically examined to confirm the diag-
nosis. The paraffin sections were dewaxed and pretreated
in 0.01 M sodium citrate buffer (pH 6.0) for 15 min at
95°C to unmask tissue antigen. These sections were then
incubated with 3% hydrogen peroxide for 30 minutes at
room temperature to block endogenous peroxidase.
Immunostaining was performed with anti-CXCR4 anti-
body (dilution 1:600) at 4°C overnight. The sections were
developed according to manufacturer's recommendations
(PV-9000 Polymer Detection System, Golden Bridge
International, USA) and counterstained with hematoxy-
lin. CXCR4 positivity was graded semiquantitatively
according to Carcangiu's method[24] as negative or weak
(total score ≤ 3) and positive (total score ≥ 4) by two inde-
pendent investigators without knowledge of the patients'
clinicopathological features and the clinical follow-up
data.Journal of Translational Medicine 2005, 3:26 http://www.translational-medicine.com/content/3/1/26
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Statistical analysis
Survival was calculated by the Kaplan-Meier method, and
the resulting curves were compared using the log-rank
test. Fisher's exact test and the χ2 test were used to analyze
the association between two categorical variables. P <0.05
was considered to be statistically significant.
Results
Expression pattern of CXCR4 in nasopharyngeal 
carcinoma
We first examined 194 NPC cases for which three-year fol-
low up information was available. All the tumors were
pathologically classified as WHO type III (undifferenti-
ated carcinoma). We observed different staining patterns
of CXCR4 in NPC tumor cells: 135 showed nucleus stain-
ing, 18 nucleus and cytoplasm staining, 2 nucleus and
cytoplasm and membrane staining, 14 cytoplasm stain-
ing, 22 cytoplasm and membrane staining, 2 membrane
staining and one negative staining (Fig. 1, C, D and 1E).
Since positive nucleus staining was the most frequently
observed pattern, we examined whether there was a corre-
lation between positive nucleus staining and survival by
dividing samples into two categories according to positive
or negative nuclear staining. No statistically significant
correlation was noted with survival. In addition, nuclear
staining was not related to intensity of staining.
Intensity of staining was also observed to be variable
among samples ranging from absent or weak to strong
(Fig. 1, C, D, E). The non-cancerous nasopharyngeal epi-
dermis stained either weakly or not at all (Fig. 1, B).
Strong CXCR4 expression was detected in 45.4% (88/
194) of the cancerous samples while the remaining dis-
played weak (105 samples) or negative (1 sample) stain-
ing. Among the samples with strong CXCR4 expression 67
showed nuclear staining, 2 nuclear and cytoplasm stain-
ing, 6 cytoplasm staining, 11 cytoplasm and membrane
staining, and 2 membrane staining. The distribution of
the CXCR4 staining is summarized in Table 1.
CXCR4 expression is correlated with metastatization and 
tumor-specific survival
Next, we analyzed the relationship between distant metas-
tases and CXCR4 staining. Metastatic rate was significantly
higher in patients with strong CXCR4 (38.6%) compared
to weak or absent (19.8%) staining (P = 0.004; Table 2).
Distant metastatic sites included lungs, brain, liver and
bone.
We further analyzed the intensity of CXCR4 staining in
relation with patient survival at 3 years follow up. During
this period, 28.4% (55/194) patients experience meta-
static recurrence and the overall survival (OS) was 75.3%
(146/194), expectedly higher than the reported 5-year sur-
vival rate for NPC [3]. Strong CXCR4 staining was associ-
ated with poor survival (OS = 67.05% versus 82.08%, P =
0.03) (Fig. 2) while no correlation was observed between
level of CXCR4 expression and age, gender, or tumor
stages (Table 2).
Expression of CXCR4 is not related to the status of 
differentiation of NPC
CXCR4 has been reported to be involved in NPC cells dif-
ferentiation [23]. Most NPC in high risk areas belong to
WHO type III (undifferentiated carcinoma) while the
more differentiated type, keratinising squamous cell carci-
noma, and the differentiated carcinoma are rarely
observed. To examine if CXCR4 expression is influenced
by the differentiation status in NPC, we collected 26 NPC
samples consisting of 6 keratinising squamous cell carci-
nomas, 10 differentiated carcinomas and 10 undifferenti-
ated carcinomas. Different staining patterns consisted of 3
nuclear, 2 nuclear and cytoplasm, 13 nuclear, cytoplasm
and membrane, 6 cytoplasm and 2 cytoplasm and mem-
brane staining (Figure 1, F). The distributing of the
CXCR4 location is summarized in Table 3. There was no
correlation between staining location and differentiation
status of the NPC samples. In addition, 34.6% (9/26)
samples stained strongly while the other 17 samples
stained weakly with no correlation with differentiation
status.
Discussion
The chemokine receptor CXCR4 is the only physiological
receptor for SDF-1. SDF-1/CXCR4 interactions have been
intensively investigated in immunology, especially with
regard to mechanism of HIV-1 infection to T lymphocytes
[13,14]. Recently attention was turned to its involvement
in cancer development and progression. Balkwill [17]
reviewed that malignant cells from different types of can-
cer expressed CXCR4 and interact with its ligand SDF-1.
Several other studies on breast, lung, pancreatic, prostate
and thyroid cancer, and glioma suggested a role of CXCR4
in the metastasatic process [5,18-22].
In the present study, we evaluated CXCR4 expression in
nasopharyngeal carcinoma by immunohistochemistry.
The observed association between strong CXCR4 expres-
sion and poor tumor-specific survival suggests that
CXCR4 expression levels influence the metastatic behav-
ior of NPC. Among the known factors associated with
NPC induction, Epstein-Barr virus (EBV) infection plays
an important role. Latent membrane protein (LMP)-1 is
the EBV-encoded protein with the most significant onco-
genic properties. In addition, LMP-1 induces NF-κB acti-
vation which has important effects on EBV-infected cell
survival [25]. NF-κB, in turn, regulates the motility of
breast cancer cells by directly up-regulating the expression
of CXCR4. Over expression of the inhibitor of NF-κB
(IκB) in breast cancer cells constitutively expressing NF-κBJournal of Translational Medicine 2005, 3:26 http://www.translational-medicine.com/content/3/1/26
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Immunohistochemical evaluation of CXCR4 expression Figure 1
Immunohistochemical evaluation of CXCR4 expression. (A) Cytoplasm and membrane staining in a breast cancer tissue as a 
positive control. (B) Weak or absent staining in a normal nasopharyngeal epidermis. (C) An undifferentiated nasopharyngeal 
carcinoma of cytoplasm staining with adjacent lymphocytes displaying predominant cytoplasmic staining. (D) An undifferenti-
ated nasopharyngeal carcinoma of membrane staining. (E) An undifferentiated nasopharyngeal carcinoma of nucleus staining. (F) 
Representative nucleus staining in a keratinising squamous cell carcinoma of nasopharynx. (All of the photomicrographs are 
high-powered magnified, ×400).
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results in reduced expression of CXCR4 and a correspond-
ing loss of SDF-1α-mediated migration in vitro [26]. This
observation may explain that the correlation between
high expression of CXCR4 in NPC cells and metastatic rate
in NPC patients which in turn affects their survival.
Our results are consistent with others' recent studies.
Murakami et al [27] suggested that a limited number of
chemokine receptors might play a critical role in deter-
mining organ-tropism in metastatic melanoma by regu-
lating chemoattraction, adhesion, and survival. In
particular, they advocated a role for chemokine receptor 7
(CCR7) in lymph node metastasis, CXCR4 in pulmonary
metastasis, and CCR10 in skin metastasis. Moreover,
CXCR4 expression in neuroblastoma primary tumors is
significantly correlated with the pattern of metastatic
spread. Similar findings were also reported from investi-
gations on prostate cancer, head and neck squamous cell
carcinoma and neuroblastoma primary tumors [28-30].
Furthermore, Lapteva et al found that small interfering
RNA (siRNA) against CXCR4 effectively abrogated breast
tumor growth in vivo implying CXCR4 as potential target
to control breast cancer growth and metastasis [31].
We noted distinct patterns of CXCR4 staining in NPC tis-
sues including nuclear, membrane and cytoplasm (Figure
1). CXCR4 is a serpentine transmembrane protein that
mediates signal transduction according to its location on
the cell membrane or in the cytoplasm. In this study, we
observed a high percentage of nuclear staining of CXCR4.
Three previous studies also identified nuclear localization
of CXCR4 in hepatocellular carcinoma [32], invasive duc-
tal mammary carcinoma [33] and non-small-cell lung
cancer (NSCLC) [19]. Kato et al [33] reported nuclear
staining of CXCR4 and defined the expression pattern of
CXCR4 as diffuse or focal observing a significant correla-
tion with the rate of lymph node metastases in breast can-
cers. Spano et al [19] found that strong CXCR4-nuclear
staining was associated with significantly better outcome
in early-stage NSCLC. However, we could not correlate
nuclear staining with clinical outcome. This inconsistency
of our findings with others' reports may be the result of
the different tissue types studied and larger studies will be
required to draw definitive conclusions.
To test whether a relationship exists between CXCR4
expression and differentiation of NPC, as reported by Xu
Table 1: Staining location of CXCR4 in the 194 undifferentiated nasopharyngeal carcinomas
Expression
Pattern Total
(n = 194)
Nucleus 
staining
Nucleus and 
cytoplasm 
staining
Nucleus and 
cytoplasm
and membrane 
staining
Cytoplasm 
staining
Cytoplasm 
and 
membrane 
staining
Membrane 
staining
Absent 
staining
Strong staining (n = 88) 67 2 0 6 11 2 0
Weak or absent staining (n = 106) 68 16 2 8 11 0 1
Table 2: Staining intensity of CXCR4 and clinical characteristics of NPC patients
Characteristics Strong staining (n = 88) Weak or absent staining (n = 106) Total (n = 194) P
Age
Median (range) 45(25–70) 46(14–72) 45 (14–72)
< 5 05 86 5 1 2 3 0 . 4 0 8
≥50 30 41 71
Gender
Female 17 27 44 0.308
Male 71 79 150
Stage
I/II 21 39 60 0.052
III/IV 67 67 134
N stage
N0 18 25 43 0.601
non-N0 70 81 151
Metastasis (follow-up)
Yes 34 21 55 0.004
No 54 85 139Journal of Translational Medicine 2005, 3:26 http://www.translational-medicine.com/content/3/1/26
Page 6 of 8
(page number not for citation purposes)
et al [23], we collected another 26 NPC samples with dif-
ferent differentiation status. As shown in Table 3, we did
not observe a correlation. Such correlation was also not
fund in other solid tumor cells.
In summary, our results identified an aberrant expression
of CXCR4 in NPC cells and the high level of CXCR4
expression correlated with distant metastasis and poor
tumor-specific survival. These results further imply that
CXCR4 could be involved in NPC progression and strong
staining of CXCR4 could be used as a predictor for NPC
prognosis.
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Kaplan-Meier analysis of tumor-specific survival in patients with NPC according to CXCR4 expression Figure 2
Kaplan-Meier analysis of tumor-specific survival in patients with NPC according to CXCR4 expression. Strong staining was 
associated with poor survival compared with weak or absent expression (OS = 67.05% versus 82.08%, P = 0.0225).
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